Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.

Next-gen weight-loss drugs like CagriSema and UBT251 could hit shelves within a year, promising more effective obesity and diabetes treatments.

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight loss drug trial.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO stock is a Buy.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks By James Waldron Mar 24, 2025 9:50am Novo Nordisk Obesity Licensing deals GLP-1 ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, were looking for a way to tackle diabetes, which the wife suffered from.